Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder

Neurocrine Biosciences’ Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million. The post Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder appeared first…

Read More

Tracking State Actions on Vaccine Policy and Access

With recent federal actions to curtail vaccine access, many states have announced actions intended to maintain broader access. This issue brief provides a snapshot of this rapidly changing landscape, tracking which states have instituted changes in response to or in anticipation of administration policy changes.

Read More

Hospital Margins Rebounded in 2023, But Rural Hospitals and Those With High Medicaid Shares Were Struggling More Than Others

This data note examines trends in hospital margins from 2018 through 2023 and how operating margins varied across different types of hospitals in 2023. It shows the industry overall experienced a rebound in 2023 after margins fell sharply the previous year, though some hospitals – particularly those in rural areas and those who see many…

Read More

CDC Vaccine Panel Ends Universal Hepatitis B Recommendation and Reviews Aluminum in Vaccines, Plus Public Awareness of Mifepristone Safety — The Monitor

This volume shares updates from the most recent CDC advisory panel meeting, changes to the CDC webpage on autism and vaccines, and polling on trust in news organizations. Additionally, it shares recent developments in AI and social media policy and new KFF poll findings about perceptions of mifepristone’s safety and prevalence.

Read More